Click on a filter below to refine your search. Remove a filter to broaden your search.
The rate of all-sites cancer incidence was 28.6% lower than expected during the height of the COVID-19 pandemic response.
Higher rates of vaccination were seen in older patients; lower rates were seen for metastatic solid tumors, with comorbidities.
Low-dose computed tomographic scan rates and mammography rates were lower than expected during March 2021 to February 2022.
The risk for severe outcomes of COVID-19 were higher for patients with hematologic versus solid cancer.
COVID-19 will remain the third-largest killer for 2022, behind heart disease and cancer, even with the reduced numbers.
The lower screening rates for cervical, breast and colorectal cancers suggest a “pattern of forgone care,” according to the researchers.
COVID-19 deaths have fallen sharply as vaccination rates have surged in recent months.